Ethylmorpholine → 3(RS)-[[N-[N-[N-[N-[N-[3-(tert-butoxycarbonyl)propionyl]-O-tert-butyl-L-alpha-aspartyl]-O-tert-butyl-L-alpha-glutamyl]-2-methyl-L-phenylalanyl]-3-methyl-L-valyl]-L-leucyl]amino]-5,5,5-trifluoro-2',4'-dimethyl-2-oxovaleranilide

HRID 635621ノート

反応式

HRID 635621 の反応式
[C:1]1([CH3:11])[CH:6]=[CH:5][C:4](S(O)(=O)=O)=[CH:3][CH:2]=1.[NH2:12][CH:13]([CH2:27][C:28]([F:31])([F:30])[F:29])[C:14](=[O:26])[C:15]([NH:17][C:18]1[CH:23]=[CH:22][C:21]([CH3:24])=[CH:20][C:19]=1[CH3:25])=[O:16].[C:32]([O:36][C:37]([CH2:39][CH2:40][C:41]([NH:43][C@H:44]([C:53]([NH:55][C@H:56]([C:66]([NH:68][C@H:69]([C:78]([NH:80][C@H:81]([C:86]([NH:88][C@H:89]([C:94](O)=[O:95])[CH2:90][CH:91]([CH3:93])[CH3:92])=[O:87])[C:82]([CH3:85])([CH3:84])[CH3:83])=[O:79])CC1C=CC=CC=1C)=[O:67])[CH2:57][CH2:58][C:59](=[O:65])[O:60][C:61]([CH3:64])([CH3:63])[CH3:62])=[O:54])[CH2:45][C:46](=[O:52])[O:47][C:48]([CH3:51])([CH3:50])[CH3:49])=[O:42])=[O:38])([CH3:35])([CH3:34])[CH3:33].[CH3:97]N(C)CCCN=C=NCC.ON1C2C=CC=CC=2N=N1.C(N1CCOCC1)C>ClCCl>[C:32]([O:36][C:37]([CH2:39][CH2:40][C:41]([NH:43][C@H:44]([C:53]([NH:55][C@H:56]([C:66]([NH:68][C@H:69]([C:78]([NH:80][C@H:81]([C:86]([NH:88][C@H:89]([C:94]([NH:12][CH:13]([CH2:27][C:28]([F:29])([F:30])[F:31])[C:14](=[O:26])[C:15]([NH:17][C:18]1[CH:23]=[CH:22][C:21]([CH3:24])=[CH:20][C:19]=1[CH3:25])=[O:16])=[O:95])[CH2:90][CH:91]([CH3:92])[CH3:93])=[O:87])[C:82]([CH3:85])([CH3:84])[CH3:83])=[O:79])[CH2:11][C:1]1[CH:6]=[CH:5][CH:4]=[CH:3][C:2]=1[CH3:97])=[O:67])[CH2:57][CH2:58][C:59](=[O:65])[O:60][C:61]([CH3:63])([CH3:64])[CH3:62])=[O:54])[CH2:45][C:46](=[O:52])[O:47][C:48]([CH3:51])([CH3:50])[CH3:49])=[O:42])=[O:38])([CH3:33])([CH3:34])[CH3:35]

参加物

7

実験手順

115 mg (0.25 mmol) of the foregoing 3(RS)-amino-5,5,5-trifluoro-2′,4′-dimethyl-2-oxovaleranilide p-toluenesulphonate (1:1), 183 mg (0.2 mmol) of N-[N-[N-[N-[N-[3-(tert-butoxycarbonyl)propionyl]-O-tert-butyl-L-α-aspartyl]-O-tert-butyl-L-α-glutamyl]-2-methyl-L-phenylalanyl]-3-methyl-L-valyl]-L-leucine, 58 mg (0.3 mmol) of 1-(3-dimethylamino-propyl)-3-ethylcarbodiimide, 30 mg (0.22 mmol) of 1-hydroxybenzotriazole and 46 mg (0.4 mmol) of N-ethylmorpholine were dissolved in 10 ml of dichloromethane and the solution was stirred at room temperature for 6 hours. The solution was then washed with 2M hydrochloric acid and saturated sodium hydrogen carbonate solution, dried over anhydrous magnesium sulphate, filtered and evaporated. The residue was chromatographed on silica gel using 3.5% methanol in dichloromethane for the elution. The solid obtained was triturated with diethyl ether and filtered off to give 61 mg of 3(RS)-[[N-[N-[N-[N-[N-[3-(tert-butoxycarbonyl)propionyl]-O-tert-butyl-L-α-aspartyl]-O-tert-butyl-L-α-glutamyl]-2-methyl-L-phenylalanyl]-3-methyl-L-valyl]-L-leucyl]amino]-5,5,5-trifluoro-2′,4′-dimethyl-2-oxovaleranilide as a white solid, MS: m/e 1188.4 [M+H]+.

後処理

  1. washThe solution was then washed with 2M hydrochloric acid and saturated sodium hydrogen carbonate solution
  2. dry with materialdried over anhydrous magnesium sulphate
  3. filtrationfiltered
  4. customevaporated
  5. customThe residue was chromatographed on silica gel using 3.5% methanol in dichloromethane for the elution
  6. customThe solid obtained
  7. customwas triturated with diethyl ether
  8. filtrationfiltered off

出典と根拠

ORDレコード
ord-533725e795c14e4698446f3906ea55ef
出典データセット
uspto-grants-2001_02
特許番号
US06187905B1

反応ノート

読み込み中…